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Long-acting nanoformulated antiretroviral therapy (nanoART) that targets monocyte-macrophages could
improve the drug's half-life and protein-binding capacities while facilitating cell and tissue depots. To
this end, ART nanoparticles that target the folic acid (FA) receptor and permit cell-based drug depots
were examined using pharmacokinetic and pharmacodynamic (PD) tests. FA receptor-targeted polox-
amer 407 nanocrystals, containing ritonavir-boosted atazanavir (ATV/r), signiﬁcantly increased drug
bioavailability and PD by ﬁve and 100 times, respectively. Drug particles administered to human pe-
ripheral blood lymphocyte reconstituted NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice and infected with HIV-1ADA
led to ATV/r drug concentrations that paralleled FA receptor beta staining in both the macrophage-rich
parafollicular areas of spleen and lymph nodes. Drug levels were higher in these tissues than what could
be achieved by either native drug or untargeted nanoART particles. The data also mirrored potent re-
ductions in viral loads, tissue viral RNA and numbers of HIV-1p24þ cells in infected and treated animals.
We conclude that FA-P407 coating of ART nanoparticles readily facilitates drug carriage and antiretroviral
responses.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The development of long-acting nanoformulated antiretroviral
therapy (nanoART) has now been realized, reﬂecting its evolution
from theory to laboratory cell culture testing to animal studies to
human clinical trials [1,2]. However, the transition from academic
research setting to clinical patient care has yet to be realized. The
needs, nonetheless, to make nanoART accessible are immediate as
limitations in ART adherence, drug fatigue, emergence of viralacology and Experimental
aha, NE 68198-5880, USA.
man).
Ltd. This is an open access article uresistance, and restrictions of drug penetration to viral reservoirs
abound [3e5]. Daily or twice daily drug administrations have a
myriad of restrictions in resource-limited settings, during co-
morbid conditions such as malabsorption syndromes and by
concomitant substance abuse. These underlie the long-term suc-
cess of currently available therapies [6e9] and are accentuated by
the lifelong ART needs.
There are several properties related to the drug and its
formulation that pose obstacles towards the broad use of nano-
ART. These include the chemical and pharmacologic properties of
ART, such as its half-life, protein-binding and hydrophobicity ca-
pacities. Additional limitations for long-term administration
revolve around adverse drug events limited by an inability to
rapidly remove ART from circulation. These have proved to bender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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oral daily dosing into a once a week, once a month or every 2e6
months injectable formulation [10,11]. Nonetheless, advantages
for long acting ART abound. These include maintenance of steady
state drug levels to limit the development of viral resistance to any
antiretroviral, thus offsetting the consequences of poor ART
compliance to daily dosing [12]. Current ART limitations include
adherence to drug regimens and the continuous long-term access
to the medicines that are required during lifelong therapy. For
these reasons, amongst others, long-term ART has ascended to the
center stage of international research activities [2,11].
Others and our laboratory have taken the concept of longer
acting ART to yet another level [12,13]. That level is now referred to
as cell- and tissue-targeted nanoART [13]. Here, the overarching
idea is to synthesize nanoART with targeted ligands that facilitate
its entry into viral target cells and tissues. This would prolong the
intracellular drug depots and further extend the drug's half-life
[13]. The idea also stems from evidence that sustained quantities
of virus persist in lymphoid tissues such as the spleen, lymph
nodes, gut-associated lymphoid tissue (GALT) and brain [14,15].
Hence, long-acting nanoART with infrequent administration could
lead to drug retention in subcellular compartments and to stable
therapeutic ART concentrations in viral sanctuaries [13,16,17]. The
advantages of biocompatible polymers, such as poloxamer 407
(P407) and poloxamer 188 (P188) covalently linked to folic acid
(FA) for encapsulating known hydrophobic antiretroviral drugs
such as atazanavir (ATV) and ritonavir (RTV) have been reported
[18,19]. These nanoparticle-based RTV boosted ATV (nanoATV/r or
P407-ATV/r) formulations show increased retention and slow
drug dissociation inside a human monocyte-derived macrophage
(MDM) carrier [16]. Improvements in intracellular drug targeting
were achieved by coating nanoART with FA-P407 [13]. We now
demonstrate that FA particle coating substantially improves drug
pharmacokinetics (PK) and pharmacodynamics (PD) with
enhanced distribution of drug to the reticuloendothelial system
such as lymphoid tissues and liver. Receptor expression is
enhanced on tissue macrophages as a consequence of nanoART
administration providing autocrine enhancement for drug distri-
bution. Moreover, when FA-nanoATV/r is parentally administered
through an intramuscular route, plasma drug levels are increased
up to 5-fold; and the concentration of drug required to achieve a
50% effective inhibitory concentration (IC50) for mice was reduced
from 250 to 50 mg/kg [13]. Pre-exposure prophylaxis (PrEP)
measured antiretroviral responses of the FA-nanoATV/r in human
peripheral blood lymphocytes (Hu-PBL) reconstituted-NOD/scid,
IL2 receptor gamma chain knockout, NOD.Cg-PrkdcscidIl2rgtm1Wjl/
SzJ (NSG) mice that were infected with HIV-1ADA.The mice showed
rapid viral reductions by measures of number of HIV-1p24þ cells
in lymphoid tissue and polymerase chain reaction (PCR) for viral
RNA. The PD seen by PrEP were validated in a chronic infection
model of HIV/AIDS where HIV-1ADA infected CD34þ human stem
cell (HSC) transplanted NSG mice were treated every other week
with parenteral intramuscular injections FA-nanoATV/r. The re-
sults showed viral RNA copies at or below the levels of
detection. These results, taken together, demonstrate the role for
FA-nanoART targeting in improving drug PK and PD. As such this
strategy would enable decreased drug dosing for long-acting
nanoART nanoformulations. The development of such a target-
ing scheme for human use is now underway.
2. Materials and methods
2.1. Chemicals
ATV-sulfatewaspurchased fromGymaLaboratories ofAmerica Inc. (Westbury,NY,
USA) and free-based using triethylamine. Free-base RTVwas purchased from Shengda
Pharmaceutical Co (Zhejiang, China). P407 (Flakes; F127) and FAwere purchased fromSigmaeAldrich (St. Louis, MO, USA). Pooled human serum was purchased from Inno-
vative Biologics (Herndon, VA, USA). Formacrophage colony-stimulating factor (MCSF)
preparation, 5/9 alpha3-18 cells (ATCC) were cultured in ATCC complete growth me-
dium and recovered supernatant ﬂuids used as a media supplement at 10% volume
[20].
2.2. Manufacture and characterization of FA-P407-ATV/r
FA-P407 was synthesized and used to manufacture FA-nanoATV/r [13]. For
preparation of FA-P407 ATV and FA-P407-RTV, FA-P407 (0.2% w/v) and P407 (0.3%
w/v) weremixed in 10mMHEPES to generatemicelles; 1% (w/v) drug was added and
mixed overnight. For preparation of P407-ATV and P407-RTV, 0.5% (w/v) P407 was
mixed with 1% drug. The suspensions were homogenized at 20,000 PSI using an
Avestin Emulsiﬂex C3 homogenizer (Avestin Inc, Ottawa, ON, Canada) until the
desired particle size (300e400 nm) was reached. Free polymers and non-
encapsulated drug particles were removed by centrifugation; the nanoparticles
were resuspended in 0.2% P407. The resulting nanosuspension was lyophilized and
stored in a desiccator protected from light. Drug loading was determined using
reversed phase high-performance liquid chromatography (HPLC) and ultra-
performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) as
described [13]. Particle size, polydispersity and zeta potential for the nano-
formulations were determined by dynamic light scattering using a Malvern Zeta-
sizer Nano-ZS instrument (Malvern Instruments Inc., Westborough, MA, USA).
2.3. Mouse FA receptor beta (mFRb) Fabs and conversion to IgG2a
A large phage display library was constructed by using peripheral blood mono-
nuclear cells (PBMC) cDNA from 40 healthy volunteers as templates for cloning the
expressed antibody gene repertoire. The library was panned using recombinant
ectodomain of mFRb conjugated to magnetic beads (Invitrogen, Carlsbad, CA, USA).
Ampliﬁed libraries of 1012 phage-displayed Fabswere incubatedwith 5, 3, 2 and 1 mg of
mFRb for 2 h at room temperature during the ﬁrst, second, third and fourth rounds of
biopanning, respectively. Clones that bound to mFRb were identiﬁed from the third
and fourth rounds of panning by using monoclonal phage ELISA. The VH and VL do-
mains of these clones were sequenced and used to generate a full-size antibody in a
mouse IgG2a format. The IgG2a was expressed in mammalian cells and puriﬁed.
Protein purity was estimated as >95% by SDS-PAGE, and protein concentration was
measured spectrophotometrically (NanoVue, GE Healthcare, Piscataway, NY).
2.4. Isolation and transplantation of human cells
Human peripheral blood lymphocytes (hu-PBL) andmonocytes were isolated by
leukapheresis from HIV-1 and hepatitis seronegative individuals by counter-current
centrifugal elutriation [21]. For reconstitution 25  106 hu-PBL per mouse were
injected intraperitoneally into 8e10 week old NOD/SCID/IL2Rgc/ (NSG) mice
obtained from a University of Nebraska Medical Center (UNMC) breeding colony
under an approved UNMC Institutional Animal Care and Use Committee protocol as
previously described [22].
2.5. Immunohistochemical staining
Male Balb/cJ mice 6e8 weeks of age (Jackson Labs, Bar Harbor, ME) were
injected intramuscularly (IM) with PBS or P407-ATV/RTV (nanoATV/r; 100 mg/kg
each drug) and sacriﬁced 36 h post treatment. Spleens were collected and ﬁxed with
10% neutral buffered formalin. The protocols used by Vector® Mouse on Mouse
(M.O.M.™) ImmPRESS HRP (peroxidase) Polymer kit (Vector Laboratories, Burlin-
game, CA, USA) were followed for decreasing the background on mouse sections.
The spleen sections were stained with a 1:200 dilution of the mFRb-speciﬁc anti-
body, washed and stained with M.O.M anti-mouse secondary antibody (Vector
laboratories), followed by 3,3-diaminobenzidine (DAB) staining. Cell nuclei were
stained with Mayer's hematoxylin.
For HIV-1p24 staining, virus-infected hu-PBL-NSG mouse tissues were collected
at day 14 in 10% neutral buffered formalin and embedded in parafﬁn. Successive
5 mm thick tissue sections were stained with mouse monoclonal antibodies for HIV-
1p24 (clone Kal-1; 1:10) and human leukocyte antigen HLA-DR (clone CR3/43;
1:100), respectively. The secondary antibodies were polymer-based DAKO envision
systems linked to horseradish peroxidase. The sections were developed with DAB.
The nuclei were counterstained with Mayer's hematoxylin. The slides were visual-
ized with a 40 objective on a Nikon Eclipse E800 microscope using NIS-Elements F
3.0 software (Nikon Instruments). The number of HIV-1p24þ cells and number of
HLA-DRþ cells per sectionwere counted and expressed as percentage of HIV-1p24þ
cells/HLA-DRþ cells in a section.
2.6. FA-nanoATV/r PK and PD
Male Balb/cJ mice (Jackson Labs), 8 weeks old, were maintained on folate deﬁ-
cient diet (Harlan Teklad TD.00434, Harlan Laboratories, Indianapolis, IN) for 2
weeks then injected with either 50 or 100 mg/kg of P407-ATV/r or FA-P407-ATV/r.
Plasmawas collected 7 or 14 days later for drug analysis. Themicewere sacriﬁced on
day 14; tissues were collected and stored at 80 C. Plasma and tissue drug levels
were determined using UPLC-MS/MS as previously described [23]. For PD studies
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prior to hu-PBL reconstitution and throughout the study. One week following
reconstitution, mice were treated with 10, 50 or 100 mg/kg of P407-ATV/r or FA-
P407-ATV/r. Native drug controls were treated with 10 or 50 mg/kg non-formulated
ATV/r. The mice were infected one day after drug treatment by intraperitoneal in-
jection with HIV-1ADA at a tissue culture infective dose 50 (TCID50) of 104 infectious
particles per mouse. Blood samples were collected from facial vein one day before
and 2 or 3, 7 and 14 days after treatment (Fig. 1A). All animal protocols were per-
formed in accordance with the UNMC Institutional Animal Care and Use Committee
requirements. The scheme for infection and treatment are presented in Fig. 1A.
Alternately, a chronic infection model was used where ﬁve month old NSG mice
were transplanted with CD34þ hematopoietic stem cells (HSC). The animals were
infected with HIV-1ADA intraperitoneally for 5 weeks at 104 TCID50/mouse. Infected
mice were either treated with 100 mg/kg FA-ATV/r or untreated. A boosting dose
was administered at two and four weeks after the ﬁrst dose. The mice were sacri-
ﬁced at week 6 and plasma was collected to determine viral loads. The mice were
maintained on folate deﬁcient diets for the duration of the experiment.
2.7. Flow cytometry
Blood samples were collected into Ca2þ-ethylenediaminetetraacetic acid
(EDTA)-coated tubes before infection and 1 and 2weeks following treatment. Spleen
cells were isolated after sacriﬁce on day 14. The blood and spleen cells were
analyzed by ﬂow cytometry for the presence of human pan-CD45, CD3, CD4 and CD8
immune markers as previously described [24].
2.8. HIV-1 RNA PCR and viral load determinations
Spleens were isolated at the time of animal sacriﬁce and RNA was extracted
using TRIzol (Invitrogen). Moloney murine leukemia virus reverse transcriptase
(Invitrogen) and random hexamers were used for reverse transcribing RNA to cDNA
[25]. Quantitative RT-PCR was performed to estimate the HIV-1gag RNA levels.
Similarly, RT-PCR was performed to determine human CD45 and GAPDH RNA levels.
Plasma from CD34þ HSC transplanted NSGmice were analyzed for viral RNA copies/
ml before and after treatment using COBAS Amplicor System v1.5 (Roche Molecular
Diagnostics, Switzerland) [26].
2.9. Statistical analyses
The data are presented as mean ± SEM. Statistical signiﬁcance between groups
was assessed using ManneWhitney U-test by Graph-Pad® Prism unless speciﬁed.
The data were considered statistically signiﬁcant if P < 0.05.
3. Results
3.1. Physicochemical characterization of nanoformulations
NanoATV/r were manufactured by high-pressure homogeniza-
tion as previously described. Particle size, charge and poly-
dispersity index for all formulations were determined by dynamic
light scattering [18,27,28]. Both ATV and RTV nanoparticles were
rod-shaped and negatively charged with zeta potential from 6
to 25 mV. The particles were uniformly distributed with poly-
dispersity indices (PDI) between 0.10 and 0.25. FA-nanoATV had a
particle size of 374 ± 3 nmwith PDI of 0.23 ± 0.01 and zeta potential
of14.0 ± 0.6 mV. FA-nanoRTV had a particle size of 390.1 ± 22 nm,
with PDI of 0.21 ± 0.01 and zeta potential of 6 ± 10 mV. The non-
targeted nanoATV/r showed similar physicochemical measure-
ments. Drug loading of the nanoformulations was determined by
HPLC as previously described [13]. Drug loadings for FA-nanoATV
and FA-nanoRTV nanoformulations were from 45 to 75% depend-
ing upon the puriﬁcation efﬁciency.
3.2. Mouse folate receptor distribution
Balb/cJ mice were administered IM either PBS or 100 mg/kg
P407-ATV/r. Themicewere then sacriﬁced 36 h post treatment. The
spleens were ﬁxed and stained with a mFRb-speciﬁc antibody fol-
lowed by anti-mouse secondary antibody and hematoxylin stain-
ing. Representative images of these stained sections are shown in
Fig. 1B and C. NanoART treatment itself appeared to increase the
level of folate receptor expression (brown) in spleen compared to
PBS treatment.3.3. PK of FA-nanoATV/r
PK and biodistribution of non-targeted and targeted nanoART
were studied in Balb/cJ mice. The mice were injected with either 50
or 100mg/kg of FA-P407-ATV/r or P407-ATV/r and sacriﬁced on day
14. The plasma ATV concentrations following treatment with FA-
P407-ATV/r were signiﬁcantly higher than with P407-ATV/r and
were dose-dependent. The mean plasma ATV concentrations at day
14 with a 100 mg/kg dose were 344 ng/ml and 31 ng/ml for FA-
P407-ATV/r and P407-ATV/r, respectively. Additionally, a 50 mg/kg
dose of FA-nanoATV/r gave a plasma concentration of 154 ng/ml
compared to 20 ng/ml ATV following non-targeted nanoATV/r
(Fig. 2A). Both doses provided ATV plasma concentrations above
the minimum effective concentration (MEC) of 150 ng/ml [29]. The
RTV plasma concentrations were not different between FA-
nanoATV/r and nanoATV/r treatment groups. Tissue drug concen-
trations showed similar trends and were also dose-dependent. A
100 mg/kg FA-P407-ATV/r dose gave 5270 ng/g and 204 ng/g
ATV concentrations in liver and spleen respectively compared to
142 ng/g and 57 ng/g in liver and spleen following P407-ATV/r
treatment. Alternately, the RTV tissue concentrations following FA-
P407-ATV/r were 338 ng/g and 49 ng/g compared to 89 ng/g and
38 ng/g for P407-ATV/r in liver and spleen, respectively (Fig. 2B).
Similar observations were found in other tissue drug concentra-
tions for P407-ATV/r and FA-P407-ATV/r. Furthermore, Balb/cJ mice
injected with 50 mg/kg FA-nanoATV/r and nanoATV/r showed
comparable trends for ATV and RTV concentrations.
PK was also measured in hu-PBL reconstituted NSGmice treated
with 10, 50 or 100 mg/kg targeted and non-targeted nanoATV/r.
The plasma and tissue concentrations were again dose-dependent.
The mean plasma ATV concentrations at day 14 with a 10 mg/kg
dose were 11 ng/ml and 18 ng/ml for nanoATV/r and FA-nanoATV/r,
respectively, which was below the MEC. However, following a
50 mg/kg dose, the average ATV plasma concentrations for nano-
ATV/r and FA-nanoATV/r were 49 and 92 ng/ml, respectively. At a
dose of 100 mg/kg nanoATV/r and FA-nanoATV/r, the observed
plasma levels were 78 ng/ml and 183 ng/ml for ATV at day 14,
respectively (Fig. S1). These results correlated with our observa-
tions in Balb/cJ mice. The average ATV concentrations at day 14
with 50 mg/kg of FA-nanoATV/r were 326.8 ng/g in liver, 54.4 ng/g
in spleen, 68.8 ng/g in lung compared to 102.1 ng/g in liver,
101.8 ng/g in spleen, and 50.4 ng/g in lung for nanoATV/r. In
contrast, ATV concentrations at day 14 with 100 mg/kg of FA-
nanoATV/r were 506 ng/g for ATV in liver, 131 ng/g in spleen,
199 ng/g in kidney and 83 ng/g in lung compared to 437 ng/g in
liver, 144 ng/g in spleen, 87 ng/g in kidney and 58.4 ng/g in lung for
nanoATV/r (Fig. S2). The variability in drug concentrations for these
tissues was attributed to the inherent variations in PBL reconsti-
tution of the mouse model. The associations between drug levels,
antiretroviral efﬁcacy and immune modulatory activities were
studied by determining HIV-1p24 antigen and gag RNA levels, and
quantitation of CD4þ T cell numbers.
3.4. CD45þ, CD3þ, CD4þ and CD8þ T cells
For these studies, blood was collected from hu-PBL-NSG mice 2
days before and 1, 6 and 13 days after viral infection. Human CD4þ
and CD8þ T cell counts were determined among CD3þ T cell
populations. Levels of CD45þ T cells were evaluated to assess
reconstitution of human cells amongst groups. The percentages of
CD45þ T cells ranged from 21 to 49, 14 to 71 and 17e61 for 10 mg/
kg, 50 mg/kg and 100 mg/kg, respectively (unpublished data). Mice
were distributed into groups normalized for CD45þ T cell recon-
stitution. CD4þ T cell populations and CD4:CD8 ratios were
decreased after 14 days relative to start times both in spleen and
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preservation of both CD4þ T cells and CD4:CD8 ratios. The mean
CD4:CD8 ratio in uninfected controls in the high dose study group
at day 14 was 0.30 þ/ 0.01. FA-P407-ATV/r and P407-ATV/r
treatment completely restored these ratios with a mean of
0.38 ± 0.20 and 0.51 ± 0.07 respectively (Fig. 3A). For a 50 mg/kg
dose, themean ± SEM CD4:CD8 ratios for FA-P407-ATV/r and P407-
ATV/r were 1.54 ± 0.77 and 1.76 ± 0.61 (Fig. 3B) respectively
compared to 9.80 ± 5.07 for uninfected mice. Both the groups
restored CD4:CD8 ratios up to ~17% compared to 3% for the PBS-
treated group. The CD4þ T cell percentages for 50 mg/kg FA-
nanoATV/r were from 31 to 84% in blood and 27e52% in spleen.
For 100 mg/kg of FA-nanoATV/r, the CD4:CD8 T cell ratios in spleen
were 0.1e0.6 compared to 0.03 to 0.1 for PBS controls, and the
means were signiﬁcantly different (P < 0.05) (Fig. 3AeC). However,
there were no signiﬁcant differences between nanoATV/r and FA-
nanoATV/r or FA-nanoATV/r and saline in blood at all doses
(Fig. 3AeC). One possible explanation is the limitations in immuneFig. 1. (A) Treatment paradigm to determine pharmacokinetics, biodistribution, efﬁcacy a
lymphocyte reconstituted non-obese diabetic, severe combined immunodeﬁcient mice (Hu-P
on macrophage. A representative photomicrograph shows the expression of mouse folate r
mice were injected intramuscularly with PBS or nanoATV/r (100 mg/kg). Mice were sacriﬁce
using the Vertex M.O.M kit. Nuclei were stained with hematoxylin. The cartoon represen
treatment.restoration observed within the hu-PBL-NSG HIV model. These
limitations would be overcome in a chronic model of HIV infection
as previously reported in CD34þ humanized mice [30].
3.5. Antiretroviral activities
We evaluated levels of HIV-1p24 antigen in parafﬁn-embedded
sections of liver, spleen (Fig. 4), lung and kidney. A dose of 10mg/kg
with all treatments did not elicit protection from viral infection. In
contrast, mice treatedwith 50 and 100mg/kg of nanoATV/r and FA-
nanoATV/r showed diminished HIV-1p24 antigen expression
(Fig. 5A and B). In the FA-nanoATV/r (50 mg/kg) group, 4/5 mice
showed 2% of viral p24 expression compared to 1/7 in the
nanoATV/r group in spleen. In the liver, the percent of HIV-1p24 for
FA-nanoATV/r (50 mg/kg) varied from 0 to 24 compared to 0 to 43
for nanoATV/r. The differences between the groups were not
statistically signiﬁcant (Fig. 5B). Furthermore, all 6 mice had 2% of
HIV-1p24 expression in spleen, liver and lung for FA-nanoATV/rnd toxicology proﬁles of nanoformulated antiretrovirals in human-peripheral blood
BL-NSG mice); Cartoon schematic showing the advantage of targeting folate receptor-b
eceptor b (mFRb) in spleen 36 h after treatment with (B) PBS and (C) nanoART. Balb/cJ
d 36 h after treatment, and spleen sections were probed with a mFRb-speciﬁc antibody
ts expression of FRb on macrophages in spleen following (D) PBS and (E) nanoART
P. Puligujja et al. / Biomaterials 41 (2015) 141e150 145(100mg/kg) group. In the P407-nanoATV/r group 4/7mice had2%
HIV-1 p24 expression in spleen, liver and lung. Also, the average
HIV-1p24 expression was statistically different between FA-
nanoATV/r and nanoATV/r groups in liver and lung at 100 mg/kg
(P < 0.05) (Fig. 5A). The decrease in HIV-1p24 antigen was dose-
dependent for both nanoATV/r and FA-nanoATV/r in liver, spleen
and lung.
We also measured HIV-1gag RNA levels in the 50 and 100 mg/kg
treatment groups by reverse transcriptase polymerase chain reac-
tion (RT-PCR) assay. For the 100 mg/kg dose, the mean levels of
HIV-1gag RNA normalized to human CD45 RNA levels were
5.8  103, 2.83  102 and 1.5  101 for PBS, nanoATV/r and FA-
nanoATV/r treated, respectively (Fig. 6A). Both the FA-P407-ATV/r
and P407-ATV/r treatments signiﬁcantly reduced HIV-1gag RNA
levels compared to the PBS-treated group (P < 0.05). Alternatively,
the mean HIV-1gag RNA normalized to CD45 RNA levels was 7 for
FA-nanoATV/r and 680 for nanoATV/r for the 50 mg/kg dose
(Fig. 6B). Overall, the FA-nanoATV/r group showed statistically
signiﬁcant reduction in HIV-1gag RNA levels compared to the
nanoATV/r and untreated groups at the 50 mg/kg dose. However,
with a 100 mg/kg dose, no statistical difference was observed be-
tween nanoATV/r and FA-nanoATV/r. A possible explanation for
this ﬁnding is that the spleen drug levels were sufﬁciently high inFig. 2. Pharmacokinetics of FA-P407- and P407-ATV/r in Balb/cJ mice. FA-P407-ATV/r and
injection on day 0, and mice were sacriﬁced on day 14. (A) Plasma was collected at indic
expressed as mean ± SEM. * Statistically different from P407-ATV/r at P < 0.05 by 2-way ANO
after FA-P407-ATV/r and P407-ATV/r treatment in Balb/cJ mice. The indicated tissues were c
MS. Data are expressed as mean ± SEM and *, **statistically different from P407-ATV/r at Pboth 100 mg/kg dose groups (Fig. S2) to lead to signiﬁcant reduc-
tion in HIV-1gag RNA. In the chronically infected mice, viral RNA
levels (RNA copies/ml) were monitored before and after treatment.
The average number of viral RNA copies/ml for treated (100 mg/kg
FA-P407-ATV/r) and untreated (infected control) animals before
treatment were 2.7  105 and 2.9  105 respectively. Following
treatment, the FA-P407-ATV/r group contained two mice with
undetectable viral levels, one with a 2-log decrease and another
with a log decrease in viral RNA copies/ml compared to the un-
treated group. The untreated group had an average of 2.2105 RNA
viral copies/ml.
4. Discussion
Long-acting injectable nanoART is rapidly emerging as part of
the general therapeutic armament for HIV/AIDS [2,11,31]. Active
research resides in the discovery of new hydrophobic drugs with
longer half-lives and protein-binding capacities over what is more
commonly prescribed [32,33]. A key component of this research
effort centers upon taking the drug formulations one step further
than by simply improving drug half-life or maintaining therapeutic
plasma drug concentrations. This can be achieved by facilitating
drug levels in the cell and tissue depots and as well as targetingP407-ATV/r were administered at a dose of 50 mg/kg or 100 mg/kg by intramuscular
ated time points and ATV and RTV levels were quantiﬁed by UPLC-MS/MS. Data are
VA and Bonferroni's posthoc test. (B) Comparison of tissue distribution of ATV and RTV
ollected on day 14 after sacriﬁce, and ATV and RTV levels were quantiﬁed by UPLC-MS/
< 0.05 and P < 0.01 by student's unpaired t-test respectively.
Fig. 3. Flow cytometric evaluation of FA-P407-ATV/r and P407-ATV/r in hu-PBL reconstituted NSG mice infected with HIV-1ADA. On day 0, PBS, Free drug or nanoATV/r (a com-
bination of ATV and rRTV) was delivered to PBLereconstituted NSG mice at doses (A) 100 mg/kg, (B) 50 mg/kg or (C) 10 mg/kg. Mice were then infected with HIV-1ADA on day 1 and
sacriﬁced on day 14. Fluorescence-activated cell sorting analyses show the ratio of human CD4þ to CD8þ T cells among total CD3þ T cells for peripheral blood and spleen from
individual mice. Data are means ± SEM and *, **statistically different at P < 0.05 and P < 0.01 by ManneWhitney U-test.
P. Puligujja et al. / Biomaterials 41 (2015) 141e150146reservoir sites of persistent infection. One means to attain this goal
is by placing speciﬁc targeting ligands on the surface of the nano-
ART formulation. This has now been achieved with FA. Here we
report substantially improved PK and PD, with similarFig. 4. Levels of HIV-1p24 antigen in liver and spleen of HIV-1 infected huPBL-reconstituted
(100 mg/kg each drug) were administered intramuscularly on day 0 to huPBL- NSG mice. M
were collected on day 14 after drug injection, then sectioned and immunostained with antantiretroviral endpoints, for FA-nanoATV/r using a lower drug dose
of 50 mg/kg, given as a parenteral injection, than what we have
previously shown with 250 mg/kg P188-ATV/r. Notably, the latter
were prepared without the FA coating [25]. We posit that suchNSG mice treated with FA-P407-ATV/r and P407-ATV/r. FA-P407-ATV/r and P407-ATV/r
ice were infected with HIV-1ADA on day 1 and sacriﬁced on day 14. Livers and spleens
ibodies speciﬁc for HLA-DR or HIV-1p24, and visualized by DAB.
Fig. 5. Comparison of antiretroviral activities of FA-P407-ATV/r and P407-ATV/r in hu-PBL reconstituted NSG mice infected with HIV-1ADA. Mice were treated on day 0 with PBS, free
drug ATV/r, P407-ATV/r or FA-P407-ATV/r at doses of (A) 100 mg/kg or (B) 50 mg/kg. Mice were then infected with HIV-1ADA on 24 h later and sacriﬁced on day 14. Parafﬁn-
embedded sections of liver, spleen and lung were probed for HIV-1p24 and HLA-DR. Antiretroviral efﬁcacy was determined by counting the number of HIV-1p24þ cells per section
and expressed as percent of HLA-DRþ cells. Data are expressed as mean ± SEM and *, **statistical differences were determined at P < 0.05 and P < 0.01 by the ManneWhitney U-
test.
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infrequently [13]. Future studies will be made to validate this idea.
The advantages of targeted nanotherapies include the mainte-
nance of therapeutic drug levels for weeks or months following a
single parenteral administration, improved compliance and patient
interest, sustained reductions in viral load, decreased viral resis-
tance against ART regimens and, as shown in the current report,
targeting of viral reservoirs [31,34,35]. As per the latter, we targeted
folate receptors on macrophages by coating crystalline ARTs with
FA-conjugated P407. This platform not only sustained plasma drug
levels but also provided improved biodistribution to sites of viral
reservoirs.
The FR is currently being used as a targeted nanoformulation
drug scheme for a broad range of cancers, degenerative and in-
ﬂammatory diseases. This approach serves as a novel means to
improve disease diagnosis and treatment primarily for cancer and
chronic inﬂammatory disorders [36e39]. Notably for ART nano-
formulation development, expression of the FR is upregulated on
activated macrophages. Such an activation can occur from the in-
teractions between nanoART and macrophages as has been previ-
ously described by our group [40]. We posit that FR overexpression
onmacrophages is clinically important for the progression of HIV-1
infection as sites of viral replication strongly coordinatewith innate
immune responses. Thus, using FA-P407-coated nanoART has both
biological and pharmacological advantages. Disease sites including
reservoirs for persistent viral infection can be readily targeted
while sustained antiretroviral responses can be realized byengagement of the nanoART itself on the macrophage cell surface.
Moreover, sites of disease, where physiological symptoms are
notable, are coordinate with macrophage activation in the brain,
lungs, lymphatics and GALT [41e43]. This coupled with observed
advantages for intracellular endosomal storage [16] has led to the
improved outcomes seen in PK and PD, as described in our current
human cell reconstituted mouse studies. Moreover, such im-
provements extend our prior works demonstrating that cell-
mediated drug delivery using nanoART yields appreciable
improvement in PK and biodistribution of ART [12].
The dosage scheme developed herein has potential clinical
application and could further reduce HIV/AIDS to an ever more
manageable disease. Herein, we demonstrated the ability of these
nanoformulations to reduce levels of infection in a HIV-1 murine
model. To this end, HIV-1ADA infected NSG mice reconstituted with
hu-PBL and treated with FA-P407-ATV/r showed signiﬁcantly
improved antiretroviral responses over either native drug or non-
targeted formulations. Interestingly, our FA-P407-coated formula-
tions had similar physicochemical characteristics to the parent
P407-coated formulations. Both were ultrastructurally long rods
with a negative surface charge. The formulations were stable at
room temperature and hence are easily stored after lyophilization.
However, signiﬁcant differences between the formulations were
observed in regards to cell entry related to receptor-mediated de-
livery of FA-nanoATV/r [13]. This ﬁnding was coordinate with FRb
expression on tissue macrophages. Moreover, the ﬁndings support
the idea that macrophages can be a carrier of nanoART to divergent
Fig. 6. Comparison of antiretroviral activities of FA-P407-ATV/r and P407-ATV/r in hu-PBL reconstituted NSG mice infected with HIV-1ADA. Mice were treated on day 0 with PBS
(untreated), free drug ATV/r, P407-ATV/r or FA-P407-ATV/r at doses of (A) 100 mg/kg or (B) 50 mg/kg. Mice were then infected with HIV-1ADA 24 h later and sacriﬁced on day 14.
HIV-1gag RNA expression in spleen was determined and normalized to human CD45 expression as a marker for human cell reconstitution. Data are expressed as mean ± SEM and
considered *, ** statistically different, at P < 0.05 and P < 0.01, by the ManneWhitney U-test.
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endosomes further demonstrates a signiﬁcant drug content in
macrophage depots [16,44].
Balb/cJ mice were administered FA-nanoATV/r and nanoATV/r,
and plasma and tissue concentrations were determined. FA-P407-
coated nanoART demonstrated up to a ﬁve times higher bioavail-
ability at 14 days than non-targeted nanoART. Plasma drug levels
were biphasic, suggesting two depots, the site of injection and
another tissue (i.e., liver). FA-nanoATV/r demonstrated better
penetration into lymph nodes and spleen than nanoATV/r. Even
though similar pharmacokinetics were obtained in hu-PBL recon-
stituted mice, a high variation in plasma and tissue drug levels was
observed. This could be due to the variability in the hu-PBL
reconstitution. We investigated the immune parameters after
treatment with three different doses of FA-nanoATV/r and
compared the response to that of the nanoATV/r and PBS groups. To
this end, CD4þ and CD8þ T cell populations were determined
during and after treatment. Mice that were PBS-treated had a sig-
niﬁcant loss in CD4þ T cells compared to FA-nanoATV/r in spleen at
all doses. Free drug treatment was also unable to prevent the
depletion in CD4þ T cell counts at 10 mg/kg. At a free drug dose of
50 mg/kg, the drug appeared to precipitate out of solution and
larger size particles were observed in the injection solution, causing
severe immune reactions at the site of injection. Hence, free drug
was not administered at a dose of 100 mg/kg. In contrast, FA-
nanoATV/r protected against CD4þ T cell depletion; however, no
statistical difference between FA-P407-coated and non-targeted
nanoATV/r was observed but both treatments restored the
CD4:CD8 ratios. One explanation for the lack of difference could be
that CD4þ T cells require longer than 2 weeks for recovery in the
hu-PBL mouse model and both treatments are equally effective at
day 14. A greater difference in CD4þ T cell counts in response to FA-
P407-ATV/r and P407-ATV/r treatment may be observed in a
chronic HIV-1 humanized mouse model. Further investigation isnecessary using CD34þ hematopoietic stem cell humanized mice.
Additionally, it is interesting to note that statistical signiﬁcance for
differences in CD4:CD8þ T cell ratios between PBS-treated and
nanoformulation treated groups was achieved in the spleen, which
is a viral reservoir, and not in the blood. This could be because of
higher numbers of T cells in the spleen compared to blood.
In addition the spleen, liver and lungs of nanoART treated hu-
PBL-NSG mice were probed with antibodies against HIV-1p24 and
HLA-DR. At a dose of 50 mg/kg, 2/5 livers and 4/5 spleens had 2%
HIVp24þ cells following FA-nanoATV/r treatment compared to 0/
6 livers and 1/6 spleens following nanoATV/r treatment (Fig. 5B).
Percent of HIV-1p24þ cells among HLA-DRþ cells paralleled tissue
drug levels. It is interesting to note that HIVp24þ cell quantitation
was a better representation of the protection offered by FA-
nanoATV/r than CD4þ/CD8þ T cell ratios in the hu-PBL-NSG
mouse model. Also, the percent of HIV-1p24þ cells was dose-
dependent for both FA-targeted and non-targeted nanoART
treatments. We also examined HIV-1 replication in the spleen by
PCR analyses. We observed that at the 50 mg/kg dose, FA-
nanoATV/r suppressed HIV-1 replication to a signiﬁcantly
greater extent compared to nanoATV/r (Fig. 6B). However, no
difference was found at a dose of 100 mg/kg. This likely reﬂects
the fact that at higher doses both treatments are equally effective.
The 50 mg/kg dose of FA-P407-ATV/r demonstrated greatest dif-
ferences in reducing HIV-1 infection. To cross validate PrEP FA-
P407-ATV/r studies, mice infected with HIV-1 for 4 weeks were
treated with FA-P407-ATV/r. The CD34þ HSC mice permit long-
term engraftment of human cells. Every other week injection of
100 mg/kg FA-P407-ATV/r resulted in up to or exceeding 2-log
decreases in viral load as measured in copies/ml when
compared against replicate untreated mice. These data serve to
validate the effectiveness of FA-P407-ATV/r. Moreover, the ﬁnd-
ings suggest that 100 mg/kg FA-P407-ATV/r can effectively sup-
press ongoing viral replication.
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improvement over a 250 mg/kg dose of our ﬁrst-generation non-
targeted formulations [25]. This mouse dose is equivalent to a hu-
man dose of approximately 4 mg/kg based on the interspecies
conversion scale of body surface area as recommended by the FDA
[45]. Such a dose would solve twomajor problems with the present
long-acting antiretroviral injectables. First, the volume of injection
can be signiﬁcantly reduced which makes an IM injection feasible
in humans. Second, the therapeutic dose can be greatly reduced
while achieving similar PK and PD outcomes.
5. Conclusions
We now demonstrate that FA-nanoATV/r signiﬁcantly improves
drug bioavailability, biodistribution and PD in a murine model of
HIV-1 infection. A major observation was the penetration of FA-
nanoATV/r to lymphoid organs such as the spleen and lymph
nodes. While the CD4þ/CD8þ T cell ratios were not statistically
different between FA-targeted and non-targeted nanoATV/r
groups; statistical signiﬁcance was observed for reduction in
percent of HIV-1p24þ cells and suppression of HIV-1gag RNA. Both
were indicative of improved therapeutic effectiveness [46,47]. A
50 mg/kg dose was the threshold for PD efﬁcacy for FA-nanoATV/r.
A biweekly administration of 100 mg/kg FA-nanoATV/r effectively
reduced viral RNA levels up to 2 logs in a chronic HIV model. In
consideration of the advantages elicited by FA-nanoATV/r, this
nanoformulation may be further considered for human testing.
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